MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

Phase 2

Terminated

• Conditions: Alzheimer's Disease

• Registration Number: NCT00362024
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-08-08
• Study First Submitted QC: 2006-08-08
• Study First Posted: 2006-08-09
• Study Start: 2006-11
• Primary Completion: 2007-11
• Study Completion: 2007-11
• Status Verified: 2016-05
• Last Update Submitted: 2016-05-13
• Last Update Posted: 2016-05-16

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Male or females
• Age >/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score </= 4, Global CDR score of 1 or 2
• Who have a reliable informant/caregiver to accompany patient to all clinic visits
• If using a symptomatic AD treatments, patients must be on stable dose for >/= 6 months

Exclusion Criteria

• Patients must not be living in nursing home or skilled nursing facility
• Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis
• Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF
• Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder
• Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)
• Various concomitant therapy restrictions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER